The FDA approved subcutaneous Opdivo for solid tumors, providing a more convenient treatment option that reduces time toxicity and enhances patient accessibility. Subcutaneous administration allows ...

FDA approved subcutaneous Opdivo for solid tumors, excluding dual immunotherapy with Yervoy, enhancing treatment convenience and accessibility. CHECKMATE-67T trial showed subcutaneous Opdivo's ...

Study reveals Depo-Provera exposure causes distinct genetic mutations in meningiomas, with increased risk of multiple tumors, particularly at the skull base The DNA footprint of meningiomas in ...

Filing a lawsuit can feel overwhelming, especially when it involves a health concern like a brain tumor potentially linked to Depo-Provera. This contraceptive shot, widely used for years ...

Several key secondary end points of the trial, like very good partial response, incidence rate of infusion reactions, and C trough at cycle 2, were also met with subcutaneous isatuximab. “The ...

It comes after a major study found women who used Depo-Provera for more than a year had a higher risk of developing a meningioma compared to women who didn't use it. Doctors say while Depo-Provera ...